In accordance with the trend of sLOX-1, the LDL concentration in the serum of patients with stage III–IV NSCLC was significantly higher than that of healthy controls and patients with stage I–II NSCLC group (p < 0.01; Figure 1(b)). This evidence concerns the gene OLR1 and non-small cell lung carcinoma.